Protalix BioTherapeutics, Inc. (PLX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Dror Bashan | President, CEO & Director | 490.67k | -- | 1967 |
| Mr. Eyal Rubin M.B.A. | Senior VP, CFO, Treasurer & Corporate Secretary | 515.36k | -- | 1976 |
| Mr. Yaron Naos B.Sc., MBA | Senior Vice President of Operations | 396.47k | -- | 1964 |
| Ms. Yael Fellous | Vice President of Human Resources | -- | -- | -- |
Protalix BioTherapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 213
Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Corporate Governance
Upcoming Events
August 12, 2025 at 12:30 PM UTC - August 18, 2025 at 12:30 PM UTC
Protalix BioTherapeutics, Inc. Earnings Date